U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT07584967) titled 'A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure' on May 04.
Brief Summary: The primary purpose of the study is to evaluate the safety and efficacy of 2 doses of AC01 compared to placebo over 12 weeks in participants with chronic advanced HFrEF.
Study Start Date: Aug. 15, 2026
Study Type: INTERVENTIONAL
Condition:
Heart Failure With Reduced Ejection Fraction (HFrEF)
Intervention:
DRUG: AC01
AC01 tablets for oral administration.
OTHER: Placebo
AC01 matching placebo tablets for oral administration.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: AnaCardio AB
...